A round-up of funding announcements this week. Other companies that have raised new venture capital funding rounds this week include Genespire, HeartVista and Particle Health and Vida.
The company has initiated a Phase II registration trial of a CAR-T that could compete against bluebird and Janssen. CEO Eric Ostertag noted it will dose the first patient in May or June.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
Longitude Capital leads round worth £25 million, which KaNDy will use to advance its non-hormonal menopause drug into Phase IIb clinical trial this year.
Tricida declined to comment about the funding beyond its ?news release, which said that the capital will be used to finance late-stage clinical trials of its lead drug candidate, TRC101.